Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.

Abstract:

BACKGROUND:Optimal extent of surgical resection (EOR) of high-grade gliomas (HGGs) remains uncertain in the elderly given the unclear benefits and potentially higher rates of mortality and morbidity associated with more extensive degrees of resection. METHODS:We undertook a meta-analysis according to a predefined protocol and systematically searched literature databases for reports about HGG EOR. Elderly patients (≥60 y) undergoing biopsy, subtotal resection (STR), and gross total resection (GTR) were compared for the outcome measures of overall survival (OS), postoperative karnofsky performance status (KPS), progression-free survival (PFS), mortality, and morbidity. Treatment effects as pooled estimates, mean differences (MDs), or risk ratios (RRs) with corresponding 95% confidence intervals (CIs) were determined using random effects modeling. RESULTS:A total of 12 607 participants from 34 studies met eligibility criteria, including our current cohort of 211 patients. When comparing overall resection (of any extent) with biopsy, in favor of the resection group were OS (MD 3.88 mo, 95% CI: 2.14-5.62, P < .001), postoperative KPS (MD 10.4, 95% CI: 6.58-14.22, P < .001), PFS (MD 2.44 mo, 95% CI: 1.45-3.43, P < .001), mortality (RR = 0.27, 95% CI: 0.12-0.61, P = .002), and morbidity (RR = 0.82, 95% CI: 0.46-1.46, P = .514) . GTR was significantly superior to STR in terms of OS (MD 3.77 mo, 95% CI: 2.26-5.29, P < .001), postoperative KPS (MD 4.91, 95% CI: 0.91-8.92, P = .016), and PFS (MD 2.21 mo, 95% CI: 1.13-3.3, P < .001) with no difference in mortality (RR = 0.53, 95% CI: 0.05-5.71, P = .600) or morbidity (RR = 0.52, 95% CI: 0.18-1.49, P = .223). CONCLUSIONS:Our findings suggest an upward improvement in survival time, functional recovery, and tumor recurrence rate associated with increasing extents of safe resection. These benefits did not result in higher rates of mortality or morbidity if considered in conjunction with known established safety measures when managing elderly patients harboring HGGs.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Almenawer SA,Badhiwala JH,Alhazzani W,Greenspoon J,Farrokhyar F,Yarascavitch B,Algird A,Kachur E,Cenic A,Sharieff W,Klurfan P,Gunnarsson T,Ajani O,Reddy K,Singh SK,Murty NK

doi

10.1093/neuonc/nou349

subject

Has Abstract

pub_date

2015-06-01 00:00:00

pages

868-81

issue

6

eissn

1522-8517

issn

1523-5866

pii

nou349

journal_volume

17

pub_type

杂志文章,meta分析,评审
  • Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.

    abstract::The subventricular zone (SVZ) lines the lateral ventricles and represents the origin of neural and some cancer stem cells. Tumors contacting the SVZ may be more invasive with higher potential to recruit migratory progenitor cells. Our specific aim was to determine whether SVZ involvement in glioblastoma multiforme (GB...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos268

    authors: Jafri NF,Clarke JL,Weinberg V,Barani IJ,Cha S

    更新日期:2013-01-01 00:00:00

  • Prospective study of cigarette smoking and adult glioma: dosage, duration, and latency.

    abstract::Tobacco products are major contributors of exogenous N-nitroso compounds, a group of potent neurocarcinogens. Overall results from studies of smoking and brain tumors have been null, but have provided little information on duration, age at smoking initiation, and latency. We prospectively examined the relation between...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-005

    authors: Holick CN,Giovannucci EL,Rosner B,Stampfer MJ,Michaud DS

    更新日期:2007-07-01 00:00:00

  • Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

    abstract::Medulloblastomas are the most common malignant tumors of the central nervous system during childhood. Radiation-induced medulloblastoma tumor recurrences are aggressive and metastatic in nature. In the present study, we demonstrate that Gadd45a expression can sensitize medulloblastoma cells to radiotherapy. We have el...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor109

    authors: Asuthkar S,Nalla AK,Gondi CS,Dinh DH,Gujrati M,Mohanam S,Rao JS

    更新日期:2011-10-01 00:00:00

  • Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults.

    abstract::Radiotherapy is ubiquitous in the treatment of patients with both primary brain tumors as well as disease which is metastatic to the brain. This therapy is not without cost, however, as cognitive decline is frequently associated with cranial radiation, particularly with whole brain radiotherapy (WBRT). The precise mec...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox195

    authors: Wilke C,Grosshans D,Duman J,Brown P,Li J

    更新日期:2018-04-09 00:00:00

  • Coexpression of neuronatin splice forms promotes medulloblastoma growth.

    abstract::Medulloblastoma (MB) is the most common pediatric brain cancer. Several important developmental pathways have been implicated in MB formation, but fewer therapeutic targets have been identified. To locate frequently overexpressed genes, we performed a comprehensive gene expression survey of MB. Our comparison of 20 pr...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-038

    authors: Siu IM,Bai R,Gallia GL,Edwards JB,Tyler BM,Eberhart CG,Riggins GJ

    更新日期:2008-10-01 00:00:00

  • The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

    abstract:BACKGROUND:Genetic and epigenetic profiling of glioblastomas has provided a comprehensive list of altered cancer genes of which only O(6)-methylguanine-methyltransferase (MGMT) methylation is used thus far as a predictive marker in a clinical setting. We investigated the prognostic significance of genetic and epigeneti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou005

    authors: Molenaar RJ,Verbaan D,Lamba S,Zanon C,Jeuken JW,Boots-Sprenger SH,Wesseling P,Hulsebos TJ,Troost D,van Tilborg AA,Leenstra S,Vandertop WP,Bardelli A,van Noorden CJ,Bleeker FE

    更新日期:2014-09-01 00:00:00

  • The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

    abstract:Background:There have been few treatment advances for patients with glioblastoma (GBM) despite increasing scientific understanding of the disease. While factors such as intrinsic tumor biology and drug delivery are challenges to developing efficacious therapies, it is unclear whether the current clinical trial landscap...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noy027

    authors: Vanderbeek AM,Rahman R,Fell G,Ventz S,Chen T,Redd R,Parmigiani G,Cloughesy TF,Wen PY,Trippa L,Alexander BM

    更新日期:2018-07-05 00:00:00

  • Limitations of stereotactic biopsy in the initial management of gliomas.

    abstract::Stereotactic biopsy is often performed for diagnostic purposes before treating patients whose imaging studies highly suggest glioma. Indications cited for biopsy include diagnosis and/or the "inoperability" of the tumor. This study questions the routine use of stereotactic biopsy in the initial management of gliomas. ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/3.3.193

    authors: Jackson RJ,Fuller GN,Abi-Said D,Lang FF,Gokaslan ZL,Shi WM,Wildrick DM,Sawaya R

    更新日期:2001-07-01 00:00:00

  • Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

    abstract:Background:Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult patients with relapsed medulloblastoma (MB) to assess tumor response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox109

    authors: Kieran MW,Chisholm J,Casanova M,Brandes AA,Aerts I,Bouffet E,Bailey S,Leary S,MacDonald TJ,Mechinaud F,Cohen KJ,Riccardi R,Mason W,Hargrave D,Kalambakas S,Deshpande P,Tai F,Hurh E,Geoerger B

    更新日期:2017-10-19 00:00:00

  • Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

    abstract::Identification of the epidermal growth factor receptor variant III (EGFRvIII) mutation in glioblastoma has become increasingly relevant in the optimization of therapy. Traditionally, determination of tumor EGFRvIII-expression has relied on tissue-based diagnostics. Here, we assess the accuracy of magnetic resonance pe...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos073

    authors: Tykocinski ES,Grant RA,Kapoor GS,Krejza J,Bohman LE,Gocke TA,Chawla S,Halpern CH,Lopinto J,Melhem ER,O'Rourke DM

    更新日期:2012-05-01 00:00:00

  • Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.

    abstract:BACKGROUND:Diffuse intrinsic pontine gliomas (DIPGs) are highly lethal childhood brain tumors. Their unique genetic makeup, pathological heterogeneity, and brainstem location all present challenges to treatment. Developing mouse models that accurately reflect each of these distinct features will be critical to advance ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz197

    authors: Patel SK,Hartley RM,Wei X,Furnish R,Escobar-Riquelme F,Bear H,Choi K,Fuller C,Phoenix TN

    更新日期:2020-03-05 00:00:00

  • Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

    abstract::Karenitecin is a highly lipophilic camptothecin analogue with a lactone ring that is relatively resistant to inactivating hydrolysis under physiologic conditions. This phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) of karenitecin in adults with recurrent malignant glioma (MG), to de...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-030

    authors: Grossman SA,Carson KA,Phuphanich S,Batchelor T,Peereboom D,Nabors LB,Lesser G,Hausheer F,Supko JG,New Approaches to Brain Tumor Therapy CNS Consortium.

    更新日期:2008-08-01 00:00:00

  • Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

    abstract:BACKGROUND:The Cancer Genome Atlas (TCGA) project is a large-scale effort with the goal of identifying novel molecular aberrations in glioblastoma (GBM). METHODS:Here, we describe an in-depth analysis of gene expression data and copy number aberration (CNA) data to classify GBMs into prognostic groups to determine cor...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not024

    authors: Kim YW,Koul D,Kim SH,Lucio-Eterovic AK,Freire PR,Yao J,Wang J,Almeida JS,Aldape K,Yung WK

    更新日期:2013-07-01 00:00:00

  • High failure rate in spinal ependymomas with long-term follow-up.

    abstract::Data on spinal ependymomas are sparse, and prognostic factors remain controversial. The primary aim of this study is to review a historical cohort, with large patient numbers and long follow-up, and provide estimates of time to progression (TTP) and survival after progression. As a secondary aim, we assess the effects...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/S1152851704001231

    authors: Gomez DR,Missett BT,Wara WM,Lamborn KR,Prados MD,Chang S,Berger MS,Haas-Kogan DA

    更新日期:2005-07-01 00:00:00

  • BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.

    abstract:BACKGROUND:Nonfunctioning pituitary adenoma (NFPA) and growth hormone pituitary adenoma (GHPA) are major subtypes of pituitary adenomas (PAs). The primary treatment is surgical resection. However, radical excision remains challenging, and few effective medical therapies are available. It is urgent to find novel targets...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa084

    authors: Shi C,Ye Z,Han J,Ye X,Lu W,Ji C,Li Z,Ma Z,Zhang Q,Zhang Y,He W,Chen Z,Cao X,Shou X,Zhou X,Wang Y,Zhang Z,Li Y,Ye H,He M,Chen H,Cheng H,Sun J,Cai J,Huang C,Ye F,Luo C,Zhou B,Ding H,Zhao Y

    更新日期:2020-08-17 00:00:00

  • APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

    abstract::Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq176

    authors: Eisele G,Roth P,Hasenbach K,Aulwurm S,Wolpert F,Tabatabai G,Wick W,Weller M

    更新日期:2011-02-01 00:00:00

  • Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007.

    abstract:Background:Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods:Using da...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox091

    authors: Leece R,Xu J,Ostrom QT,Chen Y,Kruchko C,Barnholtz-Sloan JS

    更新日期:2017-10-19 00:00:00

  • Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

    abstract:INTRODUCTION:Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos285

    authors: Alimova I,Birks DK,Harris PS,Knipstein JA,Venkataraman S,Marquez VE,Foreman NK,Vibhakar R

    更新日期:2013-02-01 00:00:00

  • Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

    abstract:BACKGROUND:Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classification-however, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinico...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not125

    authors: Laxton RC,Popov S,Doey L,Jury A,Bhangoo R,Gullan R,Chandler C,Brazil L,Sadler G,Beaney R,Sibtain N,King A,Bodi I,Jones C,Ashkan K,Al-Sarraj S

    更新日期:2013-12-01 00:00:00

  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

    abstract::The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor117

    authors: Iwamoto FM,Hottinger AF,Karimi S,Riedel E,Dantis J,Jahdi M,Panageas KS,Lassman AB,Abrey LE,Fleisher M,DeAngelis LM,Holland EC,Hormigo A

    更新日期:2011-11-01 00:00:00

  • Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.

    abstract:BACKGROUND:Micro (mi)RNAs are key regulators of gene expression and offer themselves as biomarkers for cancer development and progression. Meningioma is one of the most frequent primary intracranial tumors. As of yet, there are limited data on the role of miRNAs in meningioma of different histological subtypes and the ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov014

    authors: Ludwig N,Kim YJ,Mueller SC,Backes C,Werner TV,Galata V,Sartorius E,Bohle RM,Keller A,Meese E

    更新日期:2015-09-01 00:00:00

  • Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes.

    abstract::Treatment for medulloblastoma during childhood impairs neurocognitive function in survivors. While those diagnosed at younger ages are most vulnerable, little is known about the long-term neurocognitive, functional, and physical outcomes in survivors as they approach middle age. In this retrospective cohort study, we ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor015

    authors: Edelstein K,Spiegler BJ,Fung S,Panzarella T,Mabbott DJ,Jewitt N,D'Agostino NM,Mason WP,Bouffet E,Tabori U,Laperriere N,Hodgson DC

    更新日期:2011-05-01 00:00:00

  • Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

    abstract::We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a number of patients. The aim of this study was to ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq003

    authors: Tamborini E,Virdis E,Negri T,Orsenigo M,Brich S,Conca E,Gronchi A,Stacchiotti S,Manenti G,Casali PG,Pierotti MA,Pilotti S

    更新日期:2010-08-01 00:00:00

  • Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

    abstract::Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/5.2.89

    authors: Meyers CA,Hess KR

    更新日期:2003-04-01 00:00:00

  • Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

    abstract::Glutathione S-transferases (GSTs) are polymorphic enzymes that catalyze the glutathione conjugation of alkylating agents, platinum compounds, and free radicals formed by radiation used to treat medulloblastoma. We hypothesized that GST polymorphisms may be responsible, in part, for individual differences in toxicity a...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-089

    authors: Barahmani N,Carpentieri S,Li XN,Wang T,Cao Y,Howe L,Kilburn L,Chintagumpala M,Lau C,Okcu MF

    更新日期:2009-06-01 00:00:00

  • Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

    abstract::A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These r...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/noy170

    authors: Chiocca EA,Nassiri F,Wang J,Peruzzi P,Zadeh G

    更新日期:2019-01-01 00:00:00

  • Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

    abstract::The exact incidence of pineal germ-cell tumors is largely unknown. The tumors are rare, and the number of patients with these tumors, as reported in clinical series, has been limited. The goal of this study was to describe pineal germ-cell tumors in a large number of patients, using data from available brain tumor dat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-054

    authors: Villano JL,Propp JM,Porter KR,Stewart AK,Valyi-Nagy T,Li X,Engelhard HH,McCarthy BJ

    更新日期:2008-04-01 00:00:00

  • Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.

    abstract:BACKGROUND:Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal function and development, is implicated in several neurodegenerative conditions. Preliminary data suggest that a reduction of BDNF concentrations may lead to postchemotherapy cognitive impairment. We hypothesized that a single n...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov162

    authors: Ng T,Teo SM,Yeo HL,Shwe M,Gan YX,Cheung YT,Foo KM,Cham MT,Lee JA,Tan YP,Fan G,Yong WS,Preetha M,Loh WJ,Koo SL,Jain A,Lee GE,Wong M,Dent R,Yap YS,Ng R,Khor CC,Ho HK,Chan A

    更新日期:2016-02-01 00:00:00

  • Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

    abstract:BACKGROUND:Recent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like c...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not116

    authors: Balvers RK,Kleijn A,Kloezeman JJ,French PJ,Kremer A,van den Bent MJ,Dirven CM,Leenstra S,Lamfers ML

    更新日期:2013-12-01 00:00:00

  • Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

    abstract:Background:The mesenchymal phenotype in glioblastoma (GBM) and other cancers drives aggressiveness and treatment resistance, leading to therapeutic failure and recurrence of disease. Currently, there is no successful treatment option available against the mesenchymal phenotype. Methods:We classified patient-derived GB...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox119

    authors: Olmez I,Love S,Xiao A,Manigat L,Randolph P,McKenna BD,Neal BP,Boroda S,Li M,Brenneman B,Abounader R,Floyd D,Lee J,Nakano I,Godlewski J,Bronisz A,Sulman EP,Mayo M,Gioeli D,Weber M,Harris TE,Purow B

    更新日期:2018-01-22 00:00:00